Aziyo Biologics - AZYO Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aziyo Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZYO shares.
View AZYO analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Aziyo Biologics' stock. Their AZYO share price forecasts range from $10.00 to $13.00. On average, they expect the company's stock price to reach $11.17 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price.
View analysts price targets for AZYO or view top-rated stocks among Wall Street analysts.

Aziyo Biologics' stock was trading at $4.25 at the beginning of 2023. Since then, AZYO stock has increased by 8.0% and is now trading at $4.59.
View the best growth stocks for 2023 here.

Aziyo Biologics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,500 shares, a decline of 64.1% from the December 31st total of 18,100 shares. Based on an average daily volume of 32,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
View Aziyo Biologics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our AZYO earnings forecast.

Aziyo Biologics, Inc. (NASDAQ:AZYO) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.07. The business earned $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative trailing twelve-month return on equity of 1,819.23% and a negative net margin of 77.08%.

Aziyo Biologics updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $12.50 million-$12.70 million, compared to the consensus revenue estimate of $12.49 million.

(AZYO) raised $49 million in an initial public offering on Thursday, October 8th 2020. The company issued 2,900,000 shares at $16.00-$18.00 per share. Piper Sandler and Cowen acted as the underwriters for the IPO and Cantor and Truist Securities ​ were co-managers.

Aziyo Biologics trades on the NASDAQ under the ticker symbol "AZYO."

Aziyo Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.88%). Insiders that own company stock include Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson, Ronald K Lloyd and Thomas Englese.
View institutional ownership trends.

Shares of AZYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AZYO stock can currently be purchased for approximately $4.59.

Aziyo Biologics (NASDAQ:AZYO) has a market capitalization of $63.20 million and generates $47.39 million in revenue each year. The company earns $-24,830,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

The company employs 176 workers across the globe.

The official website for the company is www.aziyobiologics.com. The company can be reached via phone at 240-247-1170, via email at ir@aziyo.com, or via fax at 510-307-9896.